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Abstract 
Introduction: Cerebral palsy (CP) is primarily a disorder of movement and posture due to neurological 
damage before, during, or within five years of birth that prevents the brain from developing properly. 
Supportive treatments, medications, and surgery may conduct, but no optimal results have been 
obtained. The main goal of this study was to investigate the effectiveness of the intraventricular 
implantation of adipose derived neural progenitor stem cells in post-cerebral palsy patients. Methods: 14 
patients were included in this study. Small adipose tissue was isolated by small lipopectomy under local 
anesthesia, cultured and derived become neural progenitor cells. Intraventricular implantations were 
performed in the operating room. Patients were evaluated based on the Gross Motor Function 
Classification System (GMFCS) according to their motor skills before and after treatment in 12 months. 
The assessment includes cognitive functions, motoric functions and spasticity changes. Descriptive 
statistics are provided. Results and Discussion: Ten of twelve CP patients (83.33%) had a significant 
improvement after treatment. The improvement ranged from 1 to 3 levels on the GMFCS score, and 
improvement was most pronounced in motor skills and cognitive skills. There were no serious adverse 
events reported, limited to mild headaches, fever or vomiting, and all side effects resolved within few 
days. Conclusion: Because of the small sample size and non-randomized trial performed, we could not 
reach a definitive conclusion regarding the potential of intraventricular implantation. However, this 
small study shows that repeated intraventricular implantation of autologous adipose stem cells is 
advantageous. 
Keywords: Cerebral palsy, GMFCS, stem cell, Adipose tissue, Neural progenitor cells, Intraventricular 
implantation. 
Introduction 
Cerebral palsy (CP) is primarily a disorder of 
movement and posture. It occurs when there 
is neurological damage before, during, or 
within five years of birth that prevents the 
brain from developing properly [1, 2]. 
Prevalence of CP ranging from 1.5 to more 
than 4 per 1,000 live births or children of a 
defined age range[3]. About 1 in 323 children 
has been identified with CP according to 
Autism and Developmental Disabilities 
Monitoring (ADDM) [4]. Risk factors include 
preterm birth, being a twin, certain 
infections such as toxoplasmosis or rubella 
and exposure to methylmercury during 
pregnancy, a difficult delivery, and head 
trauma in the first few years of life [1]. While 
movement problems are the central feature of 
CP, difficulties with thinking, learning, 
feeling, communication and behavior often 
occur with 28% having epilepsy, 58% having 
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difficulties with communication, at least 42% 
having problems with their vision, and 23–
56% having learning disabilities[5,6]. 
Cerebral palsy is classified based on the type 
of neuromuscular deficit into (i) spastic (ii) 
dyskinetic (inclusive of choreoathetoid and 
dystonic) (iii) ataxic (IV) hypotonic and (v) 
mixed. Spastic CP is the commonest and 
accounts for 70%-75% of all cases, dyskinetic 
– 10% to 15% and ataxic is less than 5% of 
cases. It is not possible to diagnose CP in 
infants less than 6 months except in very 
severe cases. The patterns of various forms of 
CP emerge gradually with the earliest clues 
being delay in developmental milestones and 
abnormal muscle tone [7].  
Supportive treatments (include physical, 
occupational, and speech therapy), 
medications, and surgery (include 
lengthening muscles and cutting overly 
active nerves) may conducted for CP 
treatment, but no optimal results have been 
obtained [8]. As the disease progresses, these 
medications become less effective while at the 
same time they produce a complication 
marked by involuntary writhing movement 
[9].  
Surgery to place microelectrodes for deep 
brain stimulation has been used to reduce 
motor symptoms, but it is more invasive and 
full of risks [10]. In the last 10 years, 
alternative approaches to restoring neural 
function after cerebral palsy disease have 
been developed using the concept of 
neurorestoration using stem cell therapy[11]. 
Stem cells are multipotent progenitor cells 
that have been shown to have regenerative as 
well as imunomodulatory and growth 
stimulating properties.  
They have been shown in vitro to have the 
capacity to induce angiogenesis and 
differentiate into different cells types 
including cells of the nervous system [12]. 
Stem cell implantation is expected to be a 
breakthrough in curing CP patients, as it is 
expected to replace the damaged cells, 
improve the function of axons, restore the 
damaged neural circuitry, and induce healing 
through the activation of endogenous 
neurogenesis, angiogenesis and 
synaptogenesis [2,10,12].  
Nassim et al reported CP patients treated 
with intrathecal implantation of bone 
marrow mononuclear cells had an uneventful 
post-injection course with 73% of the 
evaluable patients treated having a good 
response using the Gross Motor Function 
Classification System (GMFCS). The average 
improvement was 1.3 levels with cognitive 
improvements as well [13]. The GMFCS 
describes the functional characteristics in 
five levels, from I to V, level I being the 
mildest in the following age groups: up to 2 
years, 2–4 years, 4-6 years and between 6-12 
years. For each level, separate descriptions 
are provided.  
Children in level III require orthoses and 
assisting mobility devices, while children in 
level II do not require assisting mobility 
devices after age 4. Children in level III sit 
independently, have independent floor 
mobility, and walk with assisting mobility 
devices. In level IV, affected children function 
in supported sitting but independent mobility 
is very limited.  
Children in level V lack independence even in 
basic antigravity postural control and need 
power mobility [7]. The main goal of this 
study was to investigate the effectiveness of 
the intraventricular implantation of adipose 
derived neural progenitor stem cells in post-
cerebral palsy patients. Adipose tissue-
derived stem cells are considered to be ideal 
for application in regenerative medicine, e.g. 
cerebral palsy.  
They can be easily and repeatable harvested 
using minimally invasive techniques with 
low morbidity. Adipose tissue-derived stem 
cells are multipotent and can differentiate 
into various cell types of the tri-germ 
lineages, including osteocytes, adipocytes, 
neural cells, vascular endothelial cells, 
cardiomyocytes, pancreatic β-cells, and 
hepatocytes. Interestingly, adipose tissue-
derived stem cells are characterized by 
immunosuppressive properties and low 
immunogenicity. Their secretion of trophic 
factors enforces the therapeutic and 
regenerative outcome in a wide range of 
applications [14]. 
Material and Methods 
Subjects 
This study was following the regulatory 
guidelines of the country. The patients were 
included if they had confirmed by two 
neurologists. Prior to the study, informed 
consent documents, details of the medical 
treatment and other necessary approval 
documents were delivered to all patients 
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after full explanation of the procedure and 
the safety issues involved. Fourteen patients 
were included in this study.  
The patients were evaluated based on the 
Gross Motor Function Classification System 
(GMFCS) [12] according to their motor skills 
before and after treatment in 12 months. The 
assessment include cognitive functions (all 
ways of communicating including speech, 
gesture, facial expression and augmentative, 
alternative communication), motoric 
functions (looks at movements such as 
sitting, walking and use of mobility devices), 
and spasticity changes. The assessment was 
done with the care taker and primary care 
physician. Descriptive statistics are provided. 
The following inclusion and exclusion criteria 
were used for the patient (Table 1). 
 
Table 1: Inclusion and exclusion criteria 
Inclusion Criteria Exclusion Criteria 
- Cerebral palsy patients 
- Aged minimum 6 months 
- Gross Motor Function Classification System 
(GMFCS) 
Severe: 4-5 
Mild: 1-3 
- Significant cardiac, renal or hepatic 
impaitments 
- Have encephalitis or meningitis 
- Have active infection/disease 
 
Table 2: Data progress of post-treatment patients 
No. 
Gende
r (M/F) 
Age 
(years 
old) 
48-Weeks 
Evaluation 
Improvement 
Pre-
GMFCS* 
Post-
GMFCS* 
1. M 7 4 4 
 Cognitive functions improved  understanding 
of spoken sentences and many instructions 
 No motoric and spasicity changes 
2. M 5 3 2 
 Cognitive functions improved  understanding 
many instructions 
 Motoric functions improved  head control and 
balance walking 
 Spasicity improved 
3. M 8 3 2 
 Cognitive functions improved  vocabulary 
used, understanding of spoken sentences 
 Motoric functions improved  head control and 
balance walking 
 No spasicity changes 
4. M 5 4 3 
 Cognitive functions improved  vocabulary 
used, understanding of spoken sentences 
 Motoric functions improved  head control and 
balance walking 
 No spasicity changes 
5. M 4 4 3 
 Cognitive functions improved  vocabulary 
used, understanding of spoken sentences 
concentration improved 
 Motoric functions improved  head control and 
balance walking 
No spasicity changes 
6. F 1 4 3 
 Cognitive functions improved  vocabulary 
used, understanding of spoken sentences 
 Motoric functions improved  head control and 
balance walking 
 No spasicity changes 
7. M 9 4 2 
 Cognitive functions improved  vocabulary 
used, understanding of spoken sentences and 
many instructions 
 Motoric functions improved  head control, 
balance walking and jumping 
 Spasicity improved 
8. M 9 4 4 
 Cognitive functions improved, but not 
significant 
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 No motoric and spasicity changes 
9. M 2 3 2 
 Cognitive functions improved  vocabulary 
used, understanding of spoken sentences 
 Motoric functions improved  head control and 
balance walking 
 No spasicity changes 
10. F 11 4 1 
 Cognitive functions improved  vocabulary 
used, understanding of spoken sentences and 
many instructions, more talk and cheerful, can 
express her whishes, concentration improved 
 Motoric functions improved  head control, 
balance walking and jumping 
 Significant spasicity improvement 
11. M 3 4 2 
 Cognitive functions improved  vocabulary 
used, understanding of spoken sentences 
 Motoric functions improved  head control, 
balance walking 
 Spasicity improved 
12. F 4 3 2 
 Cognitive functions improved  vocabulary 
used, understanding of spoken sentences 
 Motoric functions improved  head control, 
balance walking 
 No spasicity changes 
* GMFCS Score: 
Level 1 = perform running and jumping, but speed, balance and coordination are limited 
Level 2 = may walk with physical assistance, a handheld mobility device or used wheeled mobility 
Level 3 = use wheeled mobility when traveling long distances and may self-propel for shorter distances 
Level 4 = require physical assistance or powered mobility in most settings 
Level 5 = transported in a manual wheelchair in all settings 
Abbreviations: CP, cerebral palsy; GMFCS, Gross Motor Function Classification System; ADDM, Autism and Developmental 
Disabilities Monitoring; SVZ, sub ventricular zone 
 
Procedure and Implantation Techniques 
Isolation and intraventricular implantation 
of adipose derived neural progenitor stem 
cells were performed in the operating room. 
Autologous adipose tissue isolation was 
performed under local anaesthesia, and 
aspiration was performed with a sterile 
procedure. Neural progenitor cells were 
derived from autologous adipose tissue. 
Small adipose tissue was isolated by small 
lipopectomy under local anesthesia after 
isolation then cultured and derived become 
neural progenitor cells for around 3 weeks. 
Before used, neural progenitor cells was 
validated.  
Characterization of neural progenitor cells by 
expression of L-Dopa with 
immunocytochemistry and expression of 
Notch using flow cytometry (NPCP technique 
by Purwati).  Under general anaesthesia, 
patients were conditioned in a supine 
position. The hair was shaved just behind the 
right frontal hairline, and the area was 
washed with antiseptic solution. A mark was 
made on the right Kocher point. A 2.5-cm 
wide linear incision was made in layers 
through the periosteum. The process was 
continued by creating a burr hole in the 
calvaria and a small dural incision. An 
Ommaya reservoir was inserted into the 
ventricle, and then a maximum of 5 cc 
cerebrospinal fluid was slowly aspirated 
through the Ommaya reservoir with a wing 
needle.  
Neural progenitor cells were transplanted 
with the same wing needle (2 x 106 cells in 
3cc normal saline) and flushed with 2cc 
normal saline. The surgical wound was then 
sutured layer by layer. For booster 
implantation, the same procedures were 
performed without the open procedure or 
general anaesthesia one month after the first 
implantation. Hair did not need to be shaved, 
disinfection with povidone-iodine was 
performed at the skin and stem cell injection 
was carried out with the same dose using 
wing needle no. 25 through the subcutaneous 
transplanted Ommaya reservoir. Booster 
implantation was done twice at one-month 
intervals. 
Results 
This study obtained 9 patients (75%) were 
male, and 3 patients (25%) were female. The 
youngest patient was 1 years old, and the 
oldest was 11 years old. There were no 
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serious adverse events reported, limited to 
mild headaches, fever or vomiting, and all 
side effects resolved within few days. Ten of 
twelve patients had a significant 
improvement after stem cell therapy 
(83.33%). The improvement ranged from 1 to 
3 levels on the GMFCS scoring system. The 
improvement was most pronounced in motor 
skills and cognitive skills in 10 patients 
(83.33%) and in many cases it was the first 
feature noted to improve. Although not 
everypatient improved, overall, the majority 
of patients showed significant improvements. 
Further details on patient characteristics 
improvements are shown in Table 2. 
Discussion 
Stem cells, including adipose tissue-derived 
stem cells, have emerged as a key element of 
regenerative medicine therapies due to their 
ability to differentiate into a variety of 
different cell lineages. Their capacity of 
paracrine secretion of a broad selection of 
cytokines, chemokines, and growth factors 
make them highly clinically attractive. 
Adipose tissue-derived stem cells have been 
shown to have the capacity as anti-apoptotic, 
anti-inflammatory, immunomodulatory, anti-
scarring effects and proangiogenic, which 
make these cells promising candidates for 
cellular therapy in regenerative medicine [14, 
15]. Brain is control center of the body.  
This organ has a wide range of 
responsibilities from coordinating our 
movement to manage on emotion. For almost 
hundred years, many studies show that brain 
cell do not regenerate so need to add new 
neuron when the brain injured. In this study, 
the source of neural progenitor cells we used 
from autologous adipose tissue by small 
lipopectomy, because neural progenitor cells 
high expressed from adipose derived 
compared with from bone marrow derived, 
with expression of Notch and L-Dopa [16, 17].  
There is no standardized dose for stem cell 
therapy associated with the route of 
administration and the type of disease. For 
example, an overly high dose in 
intraparenchymal implantation can affect the 
nutrition of grafted cells and, if given 
intravascularly, cause micro-emboli and 
vessel occlusion [18]. In this study, we used 
the dose of 2 x 107 stem cells with the 
intraventricular route applied directly into 
the intracranial space. This route makes the 
dose adjustment is more flexible, because it 
can be controlled by reducing the ventricular 
fluid if necessary based on the transplant 
dose. The risk of increased intracranial 
pressure and mass effects of the body can 
also be avoided.  
This dose was administered in 3 ml of fluid to 
avoid highly concentrated doses and excess 
fluid volume. No complications, such as signs 
of increased intracranial pressure, infections 
or seizures were observed. The ventricular 
system has thin walls composed of 
ependymal cells. The permeable properties of 
ependymal cells make it quite effective for 
the treatment of certain medicines, including 
stem cell therapy targeting the brain 
parenchyma [19, 20]. On the lateral ventricle, 
the ventricular walls are surrounded by the 
sub ventricular zone (SVZ), which 
continuously produces new neurons [6].  
The location of the neurogenic niche area is 
very close to the lateral ventricle, which 
explains why the administration of stem cells 
through the intraventricular route is an 
effective method for stem cell therapy in this 
study. The lateral ventricles are easy to 
access, enabling direct stimulation of the 
SVZ. Moreover, cerebrospinal fluid is the 
endogenous regulatory factor of neuronal 
differentiation in neural regeneration, where 
the plexus choroideus produces substances 
during brain development or the 
regeneration process after brain injury [21].  
The results in all subjects showed no 
decrease in neurological status and no 
complications associated with the actions and 
effects from stem cells. Some possible side 
effects that could be observed after treatment 
are increased intracranial pressure, seizures, 
infection and rejection reaction by the body. 
However, this study demonstrated that this 
technique is safe and reported no 
complications. One other advantage, the 
presence of the reservoir, facilitates repeated 
injections when applying booster therapy.  
The Gross Motor Function Classification 
System (GMFCS) looks at movements such 
as sitting, walking and use of mobility 
devices in patients with cerebral palsy. It is 
helpful because it provides families and 
clinicians with a clear description of a child’s 
current motor function, and an idea of what 
equipment or mobility aids a child may need 
in the future. GMFCS uses 5 levels 
describing the motor function limitations and 
taking into consideration age, the use of 
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mobility aids and the quality of movement 
[22]. Levels 1 to 5 of the GMFCS describe 
worse dysfunctions and less dependence 
during mobility as the level goes up.  
Levels 1 and 2 have almost independent 
mobility, while level 3 can move with 
assistive devices, and levels 4 and 5 are 
significantly limited and dependent on their 
helpers for minor movements. There are 
several effective mechanisms of action 
involved, including neural cells regeneration, 
neurons direct stimulation, and trophic 
paracrine mediators. There is evidence those 
growth factors like stem cell may help 
improve brain regeneration [23].  
Adipose tissue may generate neurons and 
other supportive cells. Transplanted adipose-
derived neural progenitor cells infiltrate the 
brain and may help regenerate new elements 
or combat the neurodegenerative process, 
fibrosis, and oxidative insults. 
Neuroprotection may involve release of 
several neurotrophic factors that work 
through paracrine and/or-autocrine 
interactions [13].  
Sharma et al reported 85% improvement 
among cerebral palsy cases with stem cell 
therapy, where 75% reported improvement in 
muscle tone and 50% in speech among other 
symptoms. No significant adverse events 
were observed [24]. In this study, there was 
an amazing improvement in neurological 
status and the quality of life in almost all 
patients. 
Conclusion 
In this study, patients with cerebral palsy 
conducted using GMFCS after 48 weeks of 
treatment using adipose-derived neural 
progenitor cells showed an amazing 
improvement. There were no serious adverse 
events reported, limited to mild headaches, 
fever or vomiting, and all side effects resolved 
within few days. Because of the small sample 
size and non-randomised trial performed in 
this study, we could not reach a definitive 
conclusion regarding the potential of 
intraventricular implantation. However, this 
small study shows that repeated 
intraventricular implantation of autologous 
adipose stem cells is advantageous.  
Stem cell-based therapies are performing 
more experimental researches as well clinical 
trials are crucial for advancement of 
knowledge. 
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